Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.21100 http://scihub22266oqcxt.onion/10.18632/oncotarget.21100 C5663614!5663614!29137442     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2017 ; 8 (48): 84497-505 Nephropedia Template TP {{tp|p=29137442|t=2017. Prognostic value of long noncoding RNA ZFAS1 in various carcinomas: a meta-analysis |pdf=|usr=}}{{29137442}} gab.com Text Prognostic value of long noncoding RNA ZFAS1 in various carcinomas: a meta-analysis JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=29137442 #FOAvip A number of studies have revealed that zinc finger antisense 1 (ZFAS1), a long noncoding RNA (lncRNA), is aberrantly regulated in various cancers, and high ZFAS1 expression is associated with poor prognosis and increased risk of lymph node metastasis (LNM). This meta-analysis was conducted to identify the potential value of ZFAS1 as a biomarker for cancer prognosis. We searched electronic database PubMed, Web of Science, and China Wanfang Data (up to June 1, 2017) to collect all relevant studies and explore the association of ZFAS1 expression with overall survival (OS) and LNM. The results showed that cancer patients with high ZFAS1 expression had a worse OS than those with low ZFAS1 expression (HR: 1.94, 95% confidence interval [CI]: 1.41?2.47, P < 0.001), and high ZFAS1 expression was significantly associated with LNM (OR: 2.60, 95% CI: 1.54?4.42, P < 0.001). Subgroup analysis revealed that high ZFAS1 expression was significantly related to high incidence of LNM in subgroups of sample size more than 88 (OR: 3.16, 95% CI: 2.06?4.86, P < 0.001), non-digestive system malignancies (OR: 4.05, 95% CI: 2.49?6.60, P < 0.001), and studies reported in 2017 (OR: 4.86, 95% CI: 2.67?8.84, P < 0.001) without significant heterogeneity. Further meta-regression by the covariates showed that tumor type, sample size, quality score, cut off value and publication year did not result in the inter-study heterogeneity. In conclusion, the present meta-analysis demonstrates that high ZFAS1 expression may potentially serve as a reliable biomarker for poor clinical outcome in various cancers. Twit Text FOAVip Prognostic value of long noncoding RNA ZFAS1 in various carcinomas: a meta-analysis ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=29137442 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29137442 #FOAvip English Wikipedia <ref>{{Cite pmid|29137442}}</ref> Prognostic value of long noncoding RNA ZFAS1 in various carcinomas: a meta-analysis #MMPMID29137442 Dong D; Mu Z; Wang W; Xin N; Song X; Shao Y; Zhao C Oncotarget 2017[Oct]; 8 (48): 84497-505 PMID29137442show ga A number of studies have revealed that zinc finger antisense 1 (ZFAS1), a long noncoding RNA (lncRNA), is aberrantly regulated in various cancers, and high ZFAS1 expression is associated with poor prognosis and increased risk of lymph node metastasis (LNM). This meta-analysis was conducted to identify the potential value of ZFAS1 as a biomarker for cancer prognosis. We searched electronic database PubMed, Web of Science, and China Wanfang Data (up to June 1, 2017) to collect all relevant studies and explore the association of ZFAS1 expression with overall survival (OS) and LNM. The results showed that cancer patients with high ZFAS1 expression had a worse OS than those with low ZFAS1 expression (HR: 1.94, 95% confidence interval [CI]: 1.41?2.47, P < 0.001), and high ZFAS1 expression was significantly associated with LNM (OR: 2.60, 95% CI: 1.54?4.42, P < 0.001). Subgroup analysis revealed that high ZFAS1 expression was significantly related to high incidence of LNM in subgroups of sample size more than 88 (OR: 3.16, 95% CI: 2.06?4.86, P < 0.001), non-digestive system malignancies (OR: 4.05, 95% CI: 2.49?6.60, P < 0.001), and studies reported in 2017 (OR: 4.86, 95% CI: 2.67?8.84, P < 0.001) without significant heterogeneity. Further meta-regression by the covariates showed that tumor type, sample size, quality score, cut off value and publication year did not result in the inter-study heterogeneity. In conclusion, the present meta-analysis demonstrates that high ZFAS1 expression may potentially serve as a reliable biomarker for poor clinical outcome in various cancers. äPrognostic value of long noncoding RNA ZFAS1 in various carcinomas: a (epmc).pdf DeepDyve Pubget Overpricing